// App-Quantinova.ai

: Lowering the neutrophil to lymphocyte ratio by the BET inhibitor, apabetalone: potential implications for cardiovascular events in high risk patients

Researchers

Presenter

  • S. Nicholls

Principal Investigators

  • E. Kulikowski

  • C. Halliday

  • K. Lebioda

  • J. Johansson

  • M. Sweeney

  • K. Kalantar-Zadeh

Medical Centers

  • South Australian Health and Medical Research Institute, Adelaide, Australia

  • Resverlogix Corp., Calgary, Canada

  • University of California Irvine,Irvine, United States

Locations

  • Australia

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • RVX-208

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved